A Phase II Trial of atezolizumab plus carboplatin plus nab-paclitaxel as first-line therapy in metastatic Triple-negative PD-L1 positive breast cancer patients

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519514-31-00

Acronym

GIM25-CAPT

Enrollment

104

Registered

2025-01-31

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic triple-negative PD-L1 positive breast cancer

Brief summary

% Overall Survival at 2 years

Detailed description

% Overall survival at 2.5 years, Overall Survival at 2 years in HR <1% and in HR 1-10%, Post-progression survival, Objective response rate, Time to treatment failure, Incidence and severity of adverse events and seious adverse events

Interventions

DRUGPACLITAXEL ALBUMIN-BOUND

DRUGCARBOPLATIN

DRUGATEZOLIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
% Overall Survival at 2 years	—

Secondary

Measure	Time frame
% Overall survival at 2.5 years, Overall Survival at 2 years in HR <1% and in HR 1-10%, Post-progression survival, Objective response rate, Time to treatment failure, Incidence and severity of adverse events and seious adverse events	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026